Details of the Drug Combination

General Information of Drug Combination (ID: DCSUQJG)

• Drug Combination Name: BIO-300 + Topetecan
• Indication: High grade ovarian serous adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  BIO-300 (DMJ7NVI): N.A.
  Topetecan (DMAE6LK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: NCI\\/ADR-RES
  Zero Interaction Potency (ZIP) Score: 0.67
  Bliss Independence Score: 5.97
  Loewe Additivity Score: 2.14
  LHighest Single Agent (HSA) Score: 5.97

Molecular Interaction Atlas of This Drug Combination

Indication(s) of BIO-300

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
Rheumatoid arthritis	FA20	Phase 1	[3]

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[4]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[5]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCYNT8X	HL-60(TB)	Investigative	[6]
Astrocytoma	DCPYOCR	U251	Investigative	[6]
Glioma	DCJSQAO	SF-295	Investigative	[6]
Minimally invasive lung adenocarcinoma	DCWUKGQ	NCI-H322M	Investigative	[1]
Pleural epithelioid mesothelioma	DCQP1PZ	NCI-H226	Investigative	[1]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] Clinical pipeline report, company report or official report of Humanetics.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966